As more biosimilars continue to be approved across the world, it is helpful to compare the applicable regimes across major jurisdictions. We have collaborated with Brian Coggio of Fish & Richardson, and Mary Foord-Weston and...more
12/2/2019
/ Biologics ,
Biosimilars ,
BPCIA ,
Canada ,
Data Protection ,
Drug Approvals ,
EU ,
European Medicines Agency (EMA) ,
Food and Drug Administration (FDA) ,
Health Canada ,
Orphan Drugs ,
Patent Term Adjustment ,
Patent Term Extensions ,
Patented Medicines ,
Patents ,
PMNOC Regulations ,
Supplemental Protection Certificates ,
United States